Recent oncology breakthroughs showcase innovative treatments and approvals, enhancing patient outcomes in CLL, RCC, NSCLC, and CRC through targeted therapies and combinations.

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert insights and groundbreaking research.

Recent studies reveal promising outcomes for discontinuing TKI therapy in select patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, suggesting potential long-term remission.

FDA approves tafasitamab with lenalidomide and rituximab, offering a groundbreaking chemotherapy-free treatment for relapsed follicular lymphoma.

FDA updates CAR T-cell therapy labels, easing monitoring requirements and expanding access for eligible patients in oncology.

Despite major advances, real-world data show diminishing survival outcomes and treatment-limiting toxicities in second line or later CLL treatment.

During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for teclistamab in myeloma.

During a live event, Fengting Yan, MD, PhD, discussed safety outcomes from the TROPION-Breast01 and supportive care for datopotamab deruxtecan in metastatic breast cancer.

A recent trial reveals that nivolumab combined with chemotherapy significantly improves survival rates in older patients with advanced Hodgkin lymphoma.

New combination therapy of relacorilant and nab-paclitaxel shows promise in extending survival for patients with platinum-resistant ovarian cancer.

Detalimogene voraplasmid gains FDA RMAT designation, showcasing a 71% response rate in treating high-risk, BCG-unresponsive NMIBC with promising safety.

New study reveals mosunetuzumab and polatuzumab vedotin significantly improve outcomes for patients with relapsed large B-cell lymphoma, offering a chemotherapy-free option.

Discover how data analytics transforms health care by reducing costs, improving patient outcomes, and enhancing operational efficiency through innovative technologies.

During a live event, Nelson J. Chao, MD, discussed key outcomes from the trials supporting the use of ruxolitinib and axatilimab in patients with chronic graft-vs-host disease.

Oncologists face burnout from administrative work, but new technology offers solutions to streamline workflows and improve patient care.

Anixa Biosciences advances CAR T-cell therapy for recurrent ovarian cancer, targeting FSHR with promising safety and efficacy in ongoing clinical trials.

Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment efficiency in the IRAKLIA study.

Perioperative pembrolizumab enhances survival rates in advanced head and neck cancer, paving the way for earlier immunotherapy integration and future treatment strategies.

During a live event, Alfred L. Garfall, MD, discussed the dose adjustments and supportive care for toxicities seen with talquetamab in multiple myeloma.

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndromes.